CTOs on the Move

RubrYc Therapeutics

www.rubryc.com

 
RubrYc Therapeutics is a biotechnology company that integrates chemistry and computation to decode therapeutically significant protein interfaces, revolutionizing the discovery of antibody-based drugs.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

RubrYc Therapeutics raised $10M on 04/11/2018

Similar Companies

ChemNavigator

ChemNavigator is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

QED Therapeutics

QED Therapeutics, a subsidiary of BridgeBio Pharma, is a biotechnology company focused on precision medicine for FGFR-driven disorders.

Omega Therapeutics

Omega Therapeutics is a development-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programming™ platform. The OMEGA™ platform harnesses the power of epigenetics, the mechanism that controls gene expression and every aspect of an organism`s life from cell genesis, growth and differentiation to cell death. The OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by returning aberrant gene expression to a normal range without altering native nucleic acid sequences. Omega`s engineered, modular, and programmable mRNA-encoded epigenetic medicines, Omega Epigenomic Controllers™, target specific intervention points amongst the thousands of mapped and validated novel DNA-sequence-based epigenomic loci to durably tune single or multiple genes to treat and cure disease through Precision Genomic Control™. Omega is currently advancing a broad pipeline of development candidates spanning a range of disease areas, including oncology, regenerative medicine, multigenic diseases including immunology, and select monogenic diseases.

ABR--Affinity BioReagents

ABR--Affinity BioReagents is a Golden, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Wheeler Bio

A disruptive new biopharmaceutical CDMO, we are pushing the boundaries of biomanufacturing and solving an outdated industry bottleneck with a unique partnering model. By bringing together biologics drug innovators, discovery CROs, and CDMOs, we are accelerating the translation of therapeutic innovation to clinical impact.